Quale sarebbe il prezzo per Orexo AB (publ) (ORXOF)

Il prezzo per Orexo AB (publ) (ORXOF) è $1.55

Qual è la capitalizzazione di mercato per Orexo AB (publ) (ORXOF)

La capitalizzazione di mercato per Orexo AB (publ) (ORXOF) è $54.45M

Utili di Orexo AB (publ) (ORXOF)

Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.

Anno	Utile	Cambia
Non abbastanza dati per le date fornite.

Anno

Utile

Cambia

Non abbastanza dati per le date fornite.

Azienda	Utile	Differenza negli utili	Il paese
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$1.76B	-	IN

Azienda

Utile

Differenza negli utili

Il paese